This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top 4 GARP Stocks With Attractive PEG Ratios to Watch
by Urmimala Biswas
Here we present four high-growth GARP picks based on discounted PEG. These are PAK, FIVN, LTM and MFG.
MFGPositive Net Change LTMNegative Net Change FIVNPositive Net Change TAKPositive Net Change
computers finance medical medical-devices pharmaceuticals tech-stocks transportation
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
by Zacks Equity Research
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
SNYNegative Net Change BEAMPositive Net Change ADMANegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
by Zacks Equity Research
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
RHHBYNegative Net Change BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
BAYRYPositive Net Change BEAMPositive Net Change PCRXPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change RCKTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
by Zacks Equity Research
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
SNYNegative Net Change NVAXNegative Net Change BEAMPositive Net Change ADPTNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
by Kinjel Shah
NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.
AZNPositive Net Change NVOPositive Net Change JAZZNegative Net Change
pharmaceuticals
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
by Ekta Bagri
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
GRFSNegative Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
by Zacks Equity Research
VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change VTRSNegative Net Change
earnings medical pharmaceuticals
A Look at Pharma ETFs After Strong Q1 Earnings
by Sweta Killa
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
BMYNegative Net Change JNJNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change PJPNegative Net Change IHENegative Net Change XPHNegative Net Change PPHNegative Net Change FTXHNegative Net Change
earnings etfs pharmaceuticals
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
BAYRYPositive Net Change BEAMPositive Net Change CPRXPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
by Zacks Equity Research
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.
JNJNegative Net Change TEVANegative Net Change ABBVNegative Net Change
pharmaceuticals
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended
by Zacks Equity Research
CYTK reports narrower-than-expected Q1 loss. However, the target action date for aficamten in obstructive HCM has been extended by the FDA to provide time for reviewing a REMS submission made at the agency's request.
SNYNegative Net Change BAYRYPositive Net Change CYTKNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA???s accelerated approval pathway based on data from the phase I/II study in participants with Hunter syndrome.
SNYNegative Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZNegative Net Change PBYINegative Net Change NTLANegative Net Change ELEVNegative Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
REGNNegative Net Change BAYRYPositive Net Change RARENegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
NVOPositive Net Change LLYNegative Net Change BAYRYPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 7, 2025
by Zacks Equity Research
Companies in The News Are: LLY, NEM, TSLA, ABNB
LLYNegative Net Change NEMPositive Net Change TSLAPositive Net Change ABNBPositive Net Change
auto-tires-trucks pharmaceuticals
Stock Market News for May 7, 2025
by Zacks Equity Research
Wall Street closed lower on Tuesday, pulled down by health care, tech and discretionary stocks.
MRKNegative Net Change MRNANegative Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Novo Nordisk, Honeywell International and American Tower
by Zacks Equity Research
Novo Nordisk, Honeywell International and American Tower are part of the Zacks top Analyst Blog.
AMTPositive Net Change HONNegative Net Change NVOPositive Net Change
multi-sector-conglomerates pharmaceuticals reit
The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie
by Zacks Equity Research
Johnson & Johnson and AbbVie are part of the Zacks top Analyst Blog.
JNJNegative Net Change ABBVNegative Net Change
pharmaceuticals
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
by Zacks Equity Research
SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.
RHHBYNegative Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. Stock tanks 12%.
VRTXNegative Net Change ADMANegative Net Change CRSPNegative Net Change IMCRNegative Net Change
biotechs pharmaceuticals